Gait improvement after levofloxacin administration in a progressive supranuclear palsy patient

Kurihara, Masanori; Orimo, Kenta; Mano, Tatsuo; Miyano, Ryoji; Sato, Aya; Sato, Kenichiro; Ihara, Ryoko; Hayashi, Toshihiro; Toda, Tatsushi

doi:10.1016/j.prdoa.2020.100080

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kurihara et al described the case of a 55-year-old male with progressive supranuclear palsy whose levofloxacin was prescribed for pharyngitis [ 94 ]. After two days, he showed better posture, less gait freezing, and could walk a small distance without assistance.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, a levofloxacin rechallenge was attempted, revealing an improvement in bradykinesia maintained during levofloxacin use. Kurihara et al described the case of a 55-year-old male with progressive supranuclear palsy whose levofloxacin was prescribed for pharyngitis [94]. After two days, he showed better posture, less gait freezing, and could walk a small distance without assistance.…”

Section: Parkinsonism-treatment?mentioning

confidence: 99%

See 1 more Smart Citation

Fluoroquinolone-Associated Movement Disorder: A Literature Review

Rissardo

Caprara

2023

Medicines

View full text Add to dashboard Cite

Background: Fluoroquinolones (FQNs) are related to several central nervous system side effects. This review aims to evaluate the clinical-epidemiological profile, pathophysiological mechanisms, and management of FQNs-associated movement disorders (MDs). Methods: Two reviewers identified and assessed relevant reports in six databases without language restriction between 1988 and 2022. Results: A total of 45 reports containing 51 cases who developed MDs secondary to FQNs were reported. The MDs included 25 myoclonus, 13 dyskinesias, 7 dystonias, 2 cerebellar syndromes, 1 ataxia, 1 tic, and 2 undefined cases. The FQNs reported were ciprofloxacin, ofloxacin, gatifloxacin, moxifloxacin, levofloxacin, gemifloxacin, and pefloxacin. The mean and median age were 64.54 (SD: 15.45) and 67 years (range: 25–87 years). The predominant sex was male (54.16%). The mean and median time of MD onset were 6.02 (SD: 10.87) and 3 days (range: 1–68 days). The mean and median recovery time after MD treatment was 5.71 (SD: 9.01) and 3 days (range: 1–56 days). A complete recovery was achieved within one week of drug withdrawal in 80.95% of the patients. Overall, 95.83% of the individuals fully recovered after management. Conclusions: Future cases need to describe the long-term follow-up of the individuals. Additionally, FQN-induced myoclonus should include electrodiagnostic studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Parkinsonism-treatment?mentioning

confidence: 99%